PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS
NCT ID: NCT04664465
Last Updated: 2025-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2021-03-18
2026-03-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis
NCT01400464
Evaluation of Glucocorticoids Plus Rituximab in Patients with Newly-Diagnosed or Relapsing IgA Vasculitis
NCT05329090
Withdraw Drug in Stable IgG4-Related Disease
NCT04124861
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
NCT02169219
Low-dose Glucocorticoid Vasculitis Induction Study
NCT02198248
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indication to initiate prolonged glucocorticoid therapy at a dosage ≥ 15 mg/day for the treatment of an inflammatory rheumatic disease.
* Initial treatment or relapse.
* Previsional treatment duration \> 3 months.
Exclusion Criteria
* Previous corticosteroid therapy in the last 3 months at a significant dosage (\> 5 mg per day).
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'Angers
Angers, , France
CHRU de Brest
Brest, , France
CHD Vendée
La Roche-sur-Yon, , France
CH Le Mans
Le Mans, , France
CH des Pays de Morlaix
Morlaix, , France
CHU de Nantes
Nantes, , France
CHR d'Orléans
Orléans, , France
<CHU de Poitiers
Poitiers, , France
CHIC Quimper
Quimper, , France
Clinique St Exupéry
Toulouse, , France
CHU de Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Béatrice BOUVARD
Role: primary
Grégoire CORMIER
Role: primary
Emmanuelle DERNIS
Role: primary
Catherine LE HENAFF-BOURHIS
Role: primary
Benoit LE GOFF
Role: primary
Pierre POTTIER
Role: backup
Eric LESPASAILLES
Role: primary
Elisabeth GERVAIS
Role: primary
Carole DUQUENNE
Role: primary
Dr MICHAUD Martin Dr
Role: primary
Philippe GOUPILLE
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29BRC20.0274
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.